<?xml version="1.0" encoding="UTF-8"?>
<p id="Par16">According to World Health Organization (WHO) data, worldwide less than 5% of people with the chronic viral infection are aware of their condition. Effective diagnostic approaches are required in order to increase early detection of HCV, as well as a link to care and treatment services [
 <xref ref-type="bibr" rid="CR9">9</xref>]. At present, only 9 countries are on track to achieve the WHO HCV elimination targets by 2030 [
 <xref ref-type="bibr" rid="CR10">10</xref>]. Moreover, the preliminary results from an international registry showed high mortality rates in patients with coronavirus disease (COVID-19) and cirrhosis, because COVID-19 can lead to deterioration in liver function. The overall mortality rate was 40%. Patients with decompensated cirrhosis showed the highest death rate (between 43 and 63%), compared to 12% for patients with liver disease without cirrhosis [
 <xref ref-type="bibr" rid="CR11">11</xref>]. The Italian Association for the Study of the Liver and the Italian Society of Infectious and Tropical Diseases, in concert with the Association of Patients, grouped in an association called Alliance Against Hepatitis, now propose to immediately start joint HCV/COVID-19 screening [
 <xref ref-type="bibr" rid="CR12">12</xref>].
</p>
